IMP-ost : 19th Nov, 2012
Saluting the bold decision of Hamid ( CIPLA ), for giving great financial relief to cancer patients - medicine price cost reduced drastically.
After slashing cancer drug price in march-2012, Three days ago, YK Hamid ( Chairman & MD of Cipla) followed up on his promise and cut prices, by up to 63 percent, of three vital cancer drugs used in the
treatment for lung, breast, colon, pancreatic and other cancers.
The inventor of one of the drugs is Roche, against which Cipla had won a case in Delhi High court.
If the March decision, in which the price of a Rs 2.28 lakh/month drug (Nexavar) was brought down to Rs 6,600/month, symbolically broke the price barrier in cancer treatment, the subsequent decision by Cipla to reduce the prices of two more of its medicines had triggered a cascading effect.
The AIDS-treatment success story is in fact an India story. Could cancer-treatment be the next Indian success story?
India has about 2.5 million cancer patients. Annually, the country records about 800,000 new cases and 550,000 deaths.
The most common cancers in India are that of lungs, colon, prostate, bladder, breast and kidney.
Read full story at :
http://www.firstpost.com/business/ciplas-brave-act-will-cancer-treatment-go-the-aids-way-523057.html
No comments:
Post a Comment